Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deregulation of specific E2F complexes by the v-mos oncogene

C A Afshari1, N Rhodes, R S Paules

  • 1Duke University Medical Center, Department of Medicine and Center for the Study of Aging and Human Development and Durham VA a Veterans Administration Medical Center, North Carolina 27705, USA.

Oncogene
|June 26, 1997
PubMed
Summary

The c-mos proto-oncogene, when inappropriately expressed, disrupts cell cycle regulation. This leads to altered transcription factor complexes, driving uncontrolled cell growth and neoplastic transformation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring direct and indirect predictors of heart disease information seeking.

Journal of communication in healthcare·2023
Same author

The dynamic theory of reasoned action: evidence for a reverse causal process in the context of WHO handwashing guidelines.

Psychology & health·2021
Same author

The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.

Oncogene·2017
Same author

Blood gene expression profiling of an early acetaminophen response.

The pharmacogenomics journal·2016
Same author

Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen.

Clinical pharmacology and therapeutics·2015
Same author

Consistency of predictive signature genes and classifiers generated using different microarray platforms.

The pharmacogenomics journal·2010

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The c-mos proto-oncogene product is a protein kinase crucial for oocyte maturation.
  • Inappropriate expression of mos genes can lead to neoplastic progression in somatic cells.
  • v-mos-transformed cells fail to down-regulate cell cycle proteins upon serum withdrawal.

Purpose of the Study:

  • To investigate alterations in E2F and AP-1 transcription factor complexes in v-mos-transformed cells.
  • To understand the mechanism behind uncontrolled cell growth induced by mos proto-oncogene.

Main Methods:

  • Analysis of transcription factor complexes (E2F, AP-1) in NIH3T3 and v-mos-transformed NIH3T3 cells.
  • Assessment of cell cycle regulatory proteins (cyclin, cdc2) and gene expression (cdc2, DHFR, cyclin A, E2F1).

Related Experiment Videos

  • Serum withdrawal experiments to induce cell cycle arrest.

    • Main Results:

    • Serum-starved v-mos-transformed cells lack the normal G0/G1-specific p130-E2F complex.
    • These cells abnormally express S-phase E2F complexes and exhibit elevated AP-1 DNA binding activity.
    • Transcriptional activation of E2F-regulated genes (cdc2, DHFR, cyclin A, E2F1) was observed in arrested v-mos-transformed cells.

    Conclusions:

    • Altered regulation of E2F and AP-1 transcription factors contributes to uncontrolled cell proliferation in mos-transformed cells.
    • Dysregulation of transcription factor complexes and cell cycle proteins provides a mechanism for neoplastic transformation.
    • Targeting these altered pathways may offer therapeutic strategies against proto-oncogene-induced cancers.